Rapamycin‐ameliorated diabetic symptoms involved in increasing adiponectin expression in diabetic mice on a high‐fat diet | Zendy

Gong FangHua | Zendy; Ye YanNa | Zendy; Li JinMeng | Zendy; Zhao HaiYang | Zendy; Li XiaoKun | Zendy

Open Access

Rapamycin‐ameliorated diabetic symptoms involved in increasing adiponectin expression in diabetic mice on a high‐fat diet

Author(s) -

Gong FangHua,

Ye YanNa,

Li JinMeng,

Zhao HaiYang,

Li XiaoKun

Publication year - 2017

Publication title -

the kaohsiung journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.439

H-Index - 36

eISSN - 2410-8650

pISSN - 1607-551X

DOI - 10.1016/j.kjms.2017.05.008

Subject(s) - adiponectin , medicine , adipose tissue , fgf21 , endocrinology , insulin resistance , intraperitoneal injection , type 2 diabetes , diabetes mellitus , receptor , fibroblast growth factor

Recent studies showed that rapamycin improved diabetic complications. Here, we investigated the metabolic effects of rapamycin in type 2 diabetes model (T2DM) mice. Mice were treated with a daily intraperitoneal injection of rapamycin at 2 mg/kg or vehicle only for 3 weeks and were maintained on a high‐fat diet. The treated diabetic mice exhibited decreased body weight, blood glucose levels, and fat mass. FGF21 expression was suppressed in C57B/L6 mice, but adiponectin expression increased both in FGF21 KO and C57B/L6 mice. These results suggest that rapamycin may alleviate FGF21 resistance in mice on a high‐fat diet. The reduction of adipose tissue mass of the diabetic mice may be due to the increased adiponectin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research